source
- Experimental drugs to lower Lp(a) move toward market, promising billions in potential salesHigh levels of lipoprotein(a), or Lp(a), are a genetic risk factor for heart disease that affects roughly one in five people and currently has no approved therapy. Several drugmakers are moving ex…
- Akeso and Summit report ivonescimab meets primary endpoint in China Phase 3 biliary tract cancer trialAkeso Therapeutics and partner Summit Therapeutics announced that their bispecific antibody ivonescimab achieved the primary efficacy endpoint in a Phase 3 study conducted exclusively in China. Th…